Title : Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study.

Pub. Date : 2010 Dec

PMID : 20840480






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Biopsy-proven acute rejection rate at 24 weeks (primary endpoint, per-protocol analysis) was 15.8% for Tacrolimus BID versus 20.4% for Tacrolimus QD (p = 0.182; treatment difference 4.5%, 95% confidence interval-1.8%, 10.9%, just outside the prespecified 10% noninferiority margin). Tacrolimus BH3 interacting domain death agonist Homo sapiens
2 Kaplan-Meier 12-month patient and graft survival rates were 97.5% and 92.8% for Tacrolimus BID and 96.9% and 91.5% for QD. Tacrolimus BH3 interacting domain death agonist Homo sapiens